Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

(2020) Masayuki Tahara et al.   LANCET NEUROLOGY

Old and new breakthroughs in neuromyelitis optica

(2020) Hans-Peter Hartung et al.   LANCET NEUROLOGY

Evaluation of efficacy and tolerability of first-line therapies in NMOSD

(2020) Julien Poupart et al.   NEUROLOGY

A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders

(2020) Qianshuo Lu et al.   Multiple Sclerosis and Related Disorders

Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials

(2020) Tao Xue et al.   Multiple Sclerosis and Related Disorders

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options

(2019) Nicolas Collongues et al.   DRUGS

Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study

(2019) V. Shaygannejad et al.   JOURNAL OF NEUROLOGY

Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review

(2019) Clare Angeli G. Enriquez et al.   JOURNAL OF NEUROIMMUNOLOGY

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

(2019) Bruce A C Cree et al.   LANCET

Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder

(2018) Jie Lin et al.   JOURNAL OF NEUROIMMUNOLOGY

Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab

(2018) Ting Li et al.   JOURNAL OF NEUROIMMUNOLOGY

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

(2018) E. C. Tallantyre et al.   JOURNAL OF NEUROLOGY

Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study

(2018) Philippe Cabre et al.   JOURNAL OF NEUROLOGY

Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment

(2018) Su-Hyun Kim et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Racial differences in neuromyelitis optica spectrum disorder

(2018) Su-Hyun Kim et al.   NEUROLOGY

Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial

(2017) Zahra Nikoo et al.   JOURNAL OF NEUROLOGY

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response

(2017) Jan-Patrick Stellmann et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study

(2017) M. Cohen et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders

(2017) Maureen A Mealy et al.   Multiple Sclerosis Journal

Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders

(2017) Maureen A Mealy et al.   Multiple Sclerosis Journal

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study

(2016) Pietro Annovazzi et al.   JOURNAL OF NEUROLOGY

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders

(2016) Valentina Damato et al.   JAMA Neurology

Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment

(2016) George Tackley et al.   Multiple Sclerosis and Related Disorders

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses

(2015) Ingo Kleiter et al.   ANNALS OF NEUROLOGY

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability

(2015) Hélène Zéphir et al.   JOURNAL OF NEUROLOGY

Efficacy of rituximab in refractory neuromyelitis optica

(2015) N Collongues et al.   Multiple Sclerosis Journal

Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints

(2015) In Hye Jeong et al.   Multiple Sclerosis Journal

Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients

(2015) M Radaelli et al.   Multiple Sclerosis Journal

Evaluación del uso de rituximab en la neuromielitis óptica

(2015) M.J. Fernández-Megía et al.   NEUROLOGIA

Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica

(2015) Su-Hyun Kim et al.   JAMA Neurology

Efficacy of rituximab in refractory neuromyelitis optica

(2015) N Collongues et al.   Multiple Sclerosis Journal

Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints

(2015) In Hye Jeong et al.   Multiple Sclerosis Journal

Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients

(2015) M Radaelli et al.   Multiple Sclerosis Journal

Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment

(2014) Kelley Weinfurtner et al.   JOURNAL OF CHILD NEUROLOGY

Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica

(2014) Maureen A. Mealy et al.   JAMA Neurology

Experience with low-dose rituximab in off-label indications at two tertiary hospitals

(2013) J. Chay et al.   INTERNAL MEDICINE JOURNAL

Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases

(2013) Viktoria Gredler et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica

(2013) C.-S. Yang et al.   NEUROLOGY

Factors Associated With the Time to Next Attack in Neuromyelitis Optica: Accelerated Failure Time Models With Random Effects

(2013) Sung-Min Kim et al.   PLoS One

Individualized Rituximab Treatment for Neuromyelitis Optica Spectrum Disorders

(2013) Andrew McKeon et al.   JAMA Neurology

Variable results after rituximab in neuromyelitis optica

(2012) J.W. Lindsey et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders

(2012) Vincent H.L. Ip et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success

(2012) Benjamin M Greenberg et al.   Multiple Sclerosis Journal

Clinical spectrum of CNS aquaporin-4 autoimmunity

(2012) S.- H. Kim et al.   NEUROLOGY

Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years

(2011) Su-Hyun Kim   ARCHIVES OF NEUROLOGY

Impact of rituximab on relapse rate and disability in neuromyelitis optica

(2011) Gurdesh S Bedi et al.   Multiple Sclerosis Journal

Optimizing rituximab therapy for neuromyelitis optica

(2011) Dean M. Wingerchuk et al.   Nature Reviews Neurology

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

(2011) H. L. Pellkofer et al.   NEUROLOGY

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice

(2010) Samira Saadoun et al.   BRAIN

Treatment of Neuromyelitis Optica With Rituximab

(2008)   ARCHIVES OF NEUROLOGY

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

(2008) S. Jarius et al.   BRAIN